Log in to save to my catalogue
Log in to save to my catalogue

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in...

| Ask | Become a Library member

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A791845654

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

About this item

Full title

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Publisher

NewsRX LLC

Journal title

Obesity, Fitness & Wellness Week, 2024, p.37

Language

English

Formats

Reports

Publication information

Publisher

NewsRX LLC

Subjects

Subjects and topics

More information

Alternative Titles

Full title

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracmisc_A791845654

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A791845654

Other Identifiers

ISSN

1531-6386

How to access this item

Log in as a Library member

Full text available

View in old catalogue

Connecting people and collections